Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
The DOI matches its Crossref record.
Abstract
The classifications of hepatocellular carcinoma (HCC) currently used are based on prognostic factors obtained from studies performed years ago when most tumors were diagnosed at advanced stages and the survival rates were substantially poor. Recent investigations have reviewed the survival of early tumors properly selected to receive radical therapies and the natural outcome of nonsurgical HCC patients. These data enable a new staging system to be proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available. Early stage (A) includes patients with asymptomatic early tumors suitable for radical therapies--resection, transplantation or percutaneous treatments. Intermediate stage (B) comprises patients with asymptomatic multinodular HCC. Advanced stage (C) includes patients with symptomatic tumors and/or an invasive tumoral pattern (vascular invasion/extrahepatic spread). Stage B and C patients may receive palliative treatments/new agents in the setting of phase II investigations or randomized controlled trials. End-stage disease (D) contain patients with extremely grim prognosis (Okuda stage III or PST 3-4) that should merely receive symptomatic treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The management of patients with HCC has improved markedly since the first BCLC classification was proposed in 1999143.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [143]
Citations
Cites
Still being checked.
Cited by
Items 601–700 of 1,005
TACE and Sorafenib: A Good Marriage?
Abou‐Alfa, G. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9651 · Cited by 70
Zhu, Z., Huang, J., Liao, M., & Zeng, Y. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw134 · Cited by 69
Forner, A., Reig, M., Varela, M., Burrel, M., Feliú, J., Briceño, J., Sastre, J., Martí‐Bonmatí, L., Llovet, J. M., Bilbao, J. I., et al. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.01.028 · Cited by 70
Self-citationMokdad, A. A., Singal, A. G., Marrero, J. A., Zhu, H., & Yopp, A. C. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0020 · Cited by 69
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
Tojjari, A., Saeed, A. M., Singh, M., Cavalcante, L. L., Şahin, İ. H., & Saeed, A. (2023) · Vaccines · doi:10.3390/vaccines11081357 · Cited by 69
Treatment of hepatocellular carcinoma: is there an optimal strategy?
Varela, M., Sala, M., Llovet, J. M., & Bruix, J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00123-8 · Cited by 69
Self-citationImai, K., Takai, K., Hanai, T., Ideta, T., Miyazaki, T., Kochi, T., Suetsugu, A., Shiraki, M., & Shimizu, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16059612 · Cited by 69
Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma
Decaens, T., Luciani, A., Itti, E., Lesne-Hulin, A., Roudot‐Thoraval, F., Laurent, A., Zafrani, É. S., Mallat, A., & Duvoux, C. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.02.005 · Cited by 69
Clinical presentation and natural course of hepatocellular carcinoma
Bialecki, E. S., & Bisceglie, A. M. D. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200505000-00003 · Cited by 69
Lu, W., Dong, J., Huang, Z., Guo, D., Liu, Y., & Shi, S. J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05527.x · Cited by 69
Kishi, Y., Hasegawa, K., Sugawara, Y., & Kokudo, N. (2011) · International Journal of Hepatology · doi:10.4061/2011/728103 · Cited by 69
Eiró, N., Altadill, A., Salcedo, L. M. J., Rodríguez, M., González, L. O., Atienza, S., Bermúdez, S., Fernández‐García, B., Fresno-Forcelledo, M. F., Rodrigo, L., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12180 · Cited by 69
Colagrande, S., Regini, F., Taliani, G. G., Nardi, C., & Inghilesi, A. L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1041 · Cited by 69
Yang, J. D., Dai, J., Singal, A. G., Gopal, P., Addissie, B. D., Nguyen, M. H., Befeler, A. S., Reddy, K. R., Schwartz, M., Harnois, D. M., et al. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0747 · Cited by 69
Tan, L., Chen, S., Wei, G., Li, Y., Liao, J., Jin, H., Zou, Y., Huang, M., Peng, Z., Guo, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.041 · Cited by 69
Update on the Diagnosis and Treatment of Hepatocellular Carcinoma.
Ferrante, N. D., Pillai, A. A., & Singal, A. G. (2020) · PubMed Central · Cited by 71
IHPBA concordant classification of primary liver cancer: working group report
Makuuchi, M., Belghiti, J., Belli, G., Fan, S.-T., Lau, J. W. Y., Ringe, B., Strasberg, S. M., Vauthey, J., Yamaoka, Y., & Yamasaki, S. (2003) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s10534-002-0808-6 · Cited by 69
Thermal ablation of hepatocellular carcinoma
Crocetti, L., & Lencioni, R. A. (2008) · Cancer Imaging · doi:10.1102/1470-7330.2008.0004 · Cited by 69
Bonnetain, F., Paolettí, X., Collette, S., Doffoël, M., Bouché, O., Raoul, J., Rougier, P. R., Masskouri, F., Barbare, J., & Bedenne, L. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9365-y · Cited by 69
Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma
Tamai, Y., Iwasa, M., Eguchi, A., Shigefuku, R., Sugimoto, K., Hasegawa, H., & Takei, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237370 · Cited by 70
Solimando, A. G., Susca, N., Argentiero, A., Brunetti, O., Leone, P., Re, V. D., Fasano, R., Krebs, M., Petracci, E., Azzali, I., et al. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00727-7 · Cited by 71
Arita, J., Ichida, A., Nagata, R., Mihara, Y., Kawaguchi, Y., Ishizawa, T., Akamatsu, N., Kaneko, J., & Hasegawa, K. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1135 · Cited by 69
Lin, C., Kee, K., Wang, J., Lee, C., Chen, C., Changchien, C., Hu, T., Cheng, Y., Hsu, H., Wang, C., et al. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01702.x · Cited by 68
Diouf, M., Filleron, T., Barbare, J., Fin, L., Picard, C., Bouché, O., Dahan, L., Paolettí, X., & Bonnetain, F. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.019 · Cited by 69
Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma
Wan, G., Gao, F., Chen, J., Li, Y., Geng, M., Sun, L., Liu, Y., Liu, H., Yang, X. F., Wang, R., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3062-6 · Cited by 67
Torimura, T., & Iwamoto, H. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0204 · Cited by 67
Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma
Kumar, M., & Panda, D. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.03.049 · Cited by 67
Outcomes of ultrasound‐guided percutaneous argon‐helium cryoablation of hepatocellular carcinoma
Yang, Y., Wang, C., Lu, Y., Bai, W., An, L., Qu, J., Gao, X., Chen, Y., Zhou, L., Wu, Y., et al. (2011) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-011-0490-6 · Cited by 67
Lee, J. O., Lee, K., Oh, D., Kim, J. H., Im, S.-A., Kim, T. Y., & Bang, Y. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp010 · Cited by 67
Wang, H., Wu, M., & Cong, W. (2018) · Hepatology Research · doi:10.1111/hepr.13241 · Cited by 67
Pecorelli, A., Lenzi, B., Gramenzi, A., Garuti, F., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Marco, M. D., et al. (2016) · Liver International · doi:10.1111/liv.13242 · Cited by 66
Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection
Pinato, D. J., Pria, A. D., Sharma, R., & Bower, M. (2017) · AIDS · doi:10.1097/qad.0000000000001422 · Cited by 66
Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma
Kim, A. Y., Sinn, D. H., Jeong, W. K., Kim, Y. K., Kang, T. W., Ha, S. Y., Park, C. K., Choi, G., Kim, J. M., Kwon, C. H. D., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.024 · Cited by 66
Detect or not to detect very early stage hepatocellular carcinoma? The western perspective
Yang, J. D. (2019) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0010 · Cited by 66
Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002356 · Cited by 66
Ha, Y., Shim, J. H., Kim, S., Kim, K. M., Lim, Y., & Lee, H. C. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12452 · Cited by 65
Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model
Fox, R., Berhane, S., Teng, M. J., Cox, T. F., Tada, T., Toyoda, H., Kumada, T., Kagebayashi, C., Satomura, S., & Johnson, P. J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.130 · Cited by 66
Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease
Schütte, K., Bornschein, J., Kahl, S., Seidensticker, R., Arend, J., Ricke, J., & Malfertheiner, P. (2012) · Liver Cancer · doi:10.1159/000343840 · Cited by 59
Chang, I. S., Rhim, H., Kim, S. H., Kim, Y., Choi, D., Park, Y., & Lim, H. K. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3946 · Cited by 65
Bibliometric analysis of the top-cited gastroenterology and hepatology articles
Azer, S. A., & Azer, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009889 · Cited by 66
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
Takada, H., Kurosaki, M., Nakanishi, H., Takahashi, Y., Itakura, J., Tsuchiya, K., Yasui, Y., Tamaki, N., Takaura, K., Komiyama, Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198812 · Cited by 65
Takagi, K., Domagała, P., Polak, W. G., Buettner, S., & IJzermans, J. N. M. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1126-6 · Cited by 65
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Gao, Q., Wang, X., Qiu, S., Zhou, J., Shi, Y., Zhang, B., & Fan, J. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01981.x · Cited by 54
Cao, W., Li, J., Hu, C., Shen, J., Liu, X., Xu, Y., & Zhixia, Y. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1541-5 · Cited by 64
Nicolau, C., Bianchi, L., & Vilana, R. (2002) · Seminars in Ultrasound CT and MRI · doi:10.1016/s0887-2171(02)90026-0 · Cited by 64
Liver resection for HCC with cirrhosis: Surgical perspectives out of EASL/AASLD guidelines
Capussotti, L., Ferrero, A., Viganò, L., Polastri, R., & Tabone, M. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.06.005 · Cited by 64
Are, C., Afuh, C., Ravipati, L., Sasson, A. A., Ullrich, F. A., & Smith, L. M. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-1051-z · Cited by 64
DNA methylation: potential biomarker in Hepatocellular Carcinoma
Mah, W.-C., & Lee, C. G. L. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-5 · Cited by 64
Ju, M., Qiu, S., Fan, J., Zhou, J., Gao, Q., Cai, M., Li, Y., & Tang, Z. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0050-x · Cited by 64
Yu, J. I., Park, H. C., Lim, D. H., Park, W., Yoo, B. C., Paik, S. W., Koh, K. C., & Lee, J. H. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.8.1014 · Cited by 64
Kim, J., Choi, Y., Byun, J., Kim, M. K., Kang, Y. N., Kim, S. H., Lee, S., Jang, B. K., & Park, K. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.115 · Cited by 64
Current systemic treatment of hepatocellular carcinoma: A review of the literature
Chen, K.-W. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i10.1412 · Cited by 65
Gucht, A. V. D., Jreige, M., Denys, A. L., Blanc‐Durand, P., Boubaker, A., Pomoni, A., Mitsakis, P., Silva-Monteiro, M., Gnesin, S., Lalonde, M. N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184713 · Cited by 64
Gkika, E., Schultheiß, M., Bettinger, D., Maruschke, L., Neeff, H. P., Schulenburg, M., Adebahr, S., Kirste, S., Nestle, U., Thimme, R., et al. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0851-7 · Cited by 64
Ikeda, S., Lim, J. S., & Kurzrock, R. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0604 · Cited by 64
Milestones in the pathogenesis and management of primary liver cancer
Nault, J., Cheng, A., Sangro, B., & Llovet, J. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.006 · Cited by 65
Self-citationSystemic Therapies in Hepatocellular Carcinoma
Wörns, M., Weinmann, A., Schuchmann, M., & Galle, P. R. (2009) · Digestive Diseases · doi:10.1159/000218351 · Cited by 64
Guidelines for treatment of liver cancer
Livraghi, T. (2001) · European Journal of Ultrasound · doi:10.1016/s0929-8266(01)00129-x · Cited by 64
Faria, S. C., Szklaruk, J., Kaseb, A. O., Hassabo, H. M., & Elsayes, K. M. (2014) · Abdominal Imaging · doi:10.1007/s00261-014-0130-0 · Cited by 63
Cheon, J., Chon, H. J., Bang, Y. H., Park, N. H., Shin, J. W., Kim, K. M., Lee, H. C., Lee, J., Yoo, C., & Ryoo, B. (2020) · Liver Cancer · doi:10.1159/000508901 · Cited by 63
Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma
Hiotis, S. P., Rahbari, N. N., Villanueva, G., Klegar, E. K., Luan, W., Wang, Q., & Yee, H. T. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-64 · Cited by 63
Paul, S. B., Baba, C. S., Sreenivas, V., Madan, K., Gamanagatti, S. R., Batra, Y., Gupta, S. D., Panda, S. K., & Acharya, S. K. (2009) · Oncology · doi:10.1159/000231886 · Cited by 63
Varotti, G., Ramacciato, G., Ercolani, G., Grazi, G. L., Vetrone, G., Cescon, M., Gaudio, M. D., Ravaioli, M., Ziparo, V., Lauro, A., et al. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.04.008 · Cited by 63
Gwon, D. I., Ko, G., Yoon, H., Sung, K., Kim, J. H., Lee, S. S., Lee, J. M., Ohm, J.-Y., Shin, J. H., & Song, H.-Y. (2010) · Radiology · doi:10.1148/radiol.09090738 · Cited by 63
Méndez‐Sánchez, N., Ridruejo, E., de Mattos, Â. A., Chávez-Tapia, N. C., Zapata, R., Paraná, R., Mastaï, R., Strauss, E., Guevara-Casallas, L. G., Daruich, J. R., et al. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30919-6 · Cited by 63
Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm
Richani, M., Kolly, P., Knöpfli, M., Herrmann, E., Zweifel, M., von Tengg‐Kobligk, H., Candinas, D., & Dufour, J. (2015) · Annals of Hepatology · doi:10.5604/16652681.1184233 · Cited by 63
Hepatocellular Carcinoma: Epidemiology, Screening, and Assessment of Hepatic Reserve
Frager, S. Z., & Schwartz, J. M. (2020) · Current Oncology · doi:10.3747/co.27.7181 · Cited by 63
Nadarević, T., Giljača, V., Colli, A., Fraquelli, M., Casazza, G., Miletić, D., & Štimac, D. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013362.pub2 · Cited by 63
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?
Farinati, F., Sergio, A., Giacomin, A., Nolfo, M. A. D., Poggio, P. D., Benvegnù, L., Rapaccini, G., Zoli, M., Borzio, F., Giannini, E. G., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32831a86f8 · Cited by 63
Yau, T. C. C., Yao, T. J., Chan, P., Ng, K. K., Fan, S. T., & Poon, R. T. P. (2008) · Cancer · doi:10.1002/cncr.23878 · Cited by 63
Huang, Y., Chen, C., Chang, T., CHEN, S., Wang, S., Lee, M., Lin, P., Huang, G., Sheu, J., Tsai, H., et al. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03746.x · Cited by 63
Rai, P., Ansari, M. Y., Warfa, M., Al‐Hamar, H., Abinahed, J. A., Barah, A., Dakua, S. P., & Balakrishnan, S. (2023) · Cancer Medicine · doi:10.1002/cam4.6089 · Cited by 62
High USP22 expression indicates poor prognosis in hepatocellular carcinoma
Tang, B., Tang, F., Li, B., Yuan, S., Xu, Q. R., Tomlinson, S., Jin, J., Hu, W., & He, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3705 · Cited by 62
Multidisciplinary Management of Hepatocellular Carcinoma
Guy, J. E., Kelley, R. K., Roberts, J. P., Kerlan, R. K., Yao, F. Y., & Terrault, N. A. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.11.008 · Cited by 62
Notchl and Notch4 are markers for poor prognosis of hepatocellular carcinoma
Ahn, S., Hyeon, J., & Park, C.-K. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60046-6 · Cited by 62
Building the Multidisciplinary Team for Management of Patients With Hepatocellular Carcinoma
Naugler, W. E., Alsina, A. E., Frenette, C. T., Rossaro, L., & Sellers, M. T. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.03.038 · Cited by 62
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
Yeo, W., Mo, F. K. F., Chan, S. L., Leung, N. W. Y., Hui, P., Lam, W., Mok, T. S. K., Lam, K. C., Ho, W. M., Koh, J., et al. (2007) · Hepatology · doi:10.1002/hep.21572 · Cited by 62
Guglielmi, A., Ruzzenente, A., Conci, S., Valdegamberi, A., Vitali, M., Bertuzzo, F., Angelis, M. D., Mantovani, G., & Iacono, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7525 · Cited by 62
Shi, J., Guo, W., Jin, Y., Zhang, H., Pang, C., Li, J., Line, P., & Zhang, S. (2019) · Cancer Medicine · doi:10.1002/cam4.2006 · Cited by 62
New landscapes and horizons in hepatocellular carcinoma therapy
Cervello, M., Emma, M. R., Augello, G., Cusimano, A., Giannitrapani, L., Soresi, M., Akula, S. M., Abrams, S. L., Steelman, L. S., Gulino, A., et al. (2020) · Aging · doi:10.18632/aging.102777 · Cited by 63
Hucke, F., Sieghart, W., Schöniger–Hekele, M., Peck‐Radosavljevic, M., & Müller, C. (2011) · Wiener klinische Wochenschrift · doi:10.1007/s00508-011-0033-9 · Cited by 62
Puchol, M. D. F., la Parra, C., Esteban, E., Vaño, M., Forment, M., Vera, A., & Cosín, O. (2011) · Radiología (English Edition) · doi:10.1016/s2173-5107(11)70014-3 · Cited by 62
The transcription factor LSF: a novel oncogene for hepatocellular carcinoma.
Santhekadur, P. K., Rajasekaran, D., Siddiq, A., Gredler, R., Chen, D., Schaus, S. E., Hansen, U. M., Fisher, P. B., & Sarkar, D. (2012) · Europe PMC (PubMed Central) · Cited by 62
Zhao, L., Yang, D., Ma, X., Liu, M., Wu, D., Zhang, X., Ruan, D., Lin, J.-X., Wen, J., Chen, J., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30663 · Cited by 61
Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment
Papaconstantinou, D., Tsilimigras, D. I., & Pawlik, T. M. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s342266 · Cited by 61
AEG-1/MTDH/LYRIC in Liver Cancer
Sarkar, D. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-401676-7.00007-3 · Cited by 61
Terzi, E., Terenzi, L., Venerandi, L., Croci, L., Renzulli, M., Mosconi, C., Allegretti, G., Granito, A., Golfieri, R., Bolondi, L., et al. (2014) · Digestive Diseases · doi:10.1159/000368007 · Cited by 61
Wu, S., Lin, Y., Ye, H., Li, F., Xiong, X., & Cheng, N. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24297 · Cited by 61
Tada, T., Kumada, T., Toyoda, H., Tsuji, K., Hiraoka, A., Itobayashi, E., Nouso, K., Kariyama, K., Ishikawa, T., Hirooka, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13257 · Cited by 61
Medical Management of Hepatocellular Carcinoma
Rich, N. E., Yopp, A. C., & Singal, A. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022996 · Cited by 61
Imai, K., Takai, K., Watanabe, S., Hanai, T., Suetsugu, A., Shiraki, M., & Shimizu, M. (2017) · Nutrients · doi:10.3390/nu9101054 · Cited by 61
Cai, W., He, B., Hu, M., Zhang, W., Xiao, D., Yu, H., Song, Q., Xiang, N., Yang, J., He, S., et al. (2018) · Surgical Oncology · doi:10.1016/j.suronc.2018.11.013 · Cited by 61
Safety of hepatic resection in overweight and obese patients with cirrhosis
Cucchetti, A., Cescon, M., Ercolani, G., Gioia, P. D., Peri, E., & Pinna, A. D. (2011) · British journal of surgery · doi:10.1002/bjs.7516 · Cited by 61
Evaluation and Management of Hepatocellular Carcinoma
Kulik, L., & Chokechanachaisakul, A. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2014.09.002 · Cited by 60
Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype
Carr, B. I., Guerra, V., Giannini, E. G., Farinati, F., Ciccarese, F., Rapaccini, G. L., Marco, M. D., Benvegnù, L., Zoli, M., Borzio, F., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.006 · Cited by 60
Mourad, A., Deuffic‐Burban, S., Ganne‐Carrié, N., Renaut-Vantroys, T., Rosa, I., Bouvier, A., Launoy, G. D., Cattan, S., Louvet, A., Dharancy, S., et al. (2013) · Hepatology · doi:10.1002/hep.26944 · Cited by 60
Radiotherapy and hepatocellular carcinoma: update and review of the literature.
Ursino, S., Greco, C., Cartei, F., Colosimo, C., Stefanelli, A., Cacopardo, B. S., Berretta, M., & Fiorica, F. (2012) · PubMed · Cited by 60
Meguro, M., Mizuguchi, T., Nishidate, T., Okita, K., Ishii, M., Ota, S., Ueki, T., Akizuki, E., & Hirata, K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i16.4933 · Cited by 60
Zhang, Z.-F., Feng, X.-S., Chen, H., Duan, Z.-J., Wang, L.-X., Yang, D., Liu, P.-X., Zhang, Q.-P., Jin, Y.-L., Sun, Z.-G., et al. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0474-8 · Cited by 57
Metadata
- Authors
- Llovet, J., Brú, C., & Bruix, J.
- Affiliations
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 1999
- Volume
- 19
- Issue
- 03
- Pages
- 329-338
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2147172608
- Cited by
- 3,805
- References
- 0
- Citations by year
- 2026: 70 · 2025: 117 · 2024: 162 · 2023: 211 · 2022: 269 · 2021: 280 · 2020: 279 · 2019: 215 · 2018: 206 · 2017: 218 · 2016: 216 · 2015: 220 · 2014: 219 · 2013: 163 · 2012: 154
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, prognosis, tumor staging, radical treatment, liver transplantation, hepatectomy, percutaneous treatment, vascular invasion, extrahepatic spread, palliative care, Okuda staging
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Prognosis, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.